Clinical trial
A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
NCT00363376 · Lindner Center of HOPE, Other · Completed
Key facts
| NCT number | NCT00363376 |
|---|---|
| Title | A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain |
| Official title | A Double-Blind, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain |
| Lead sponsor | Lindner Center of HOPE, Other |
| Collaborators | Eli Lilly and Company Industry University of Cincinnati |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Weight Gain |
| Intervention type | Drug |
| Interventions | zonisamide, olanzapine, Zonisamide, Sugar Pill (placebo) |
| Enrollment | 42 |
| Start date | Jan 1, 2008 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Aug 15, 2006 |
| Last update posted | Apr 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: